The Fund will invest in start ups across the entire value chain (from seed to patient). Investing in innovative companies and teams working on novel therapeutics utilising medical cannabis and other molecules that target an important signalling and regulatory system for maintaining health and fighting disease, the endocannabinoid system. The MEDCAN Fund will target Qualifying Companies that exploit the therapeutic potential of the endocannabinoid system for use in global markets. It will not invest in growing or producing cannabis, nor will the Fund be involved in businesses or activities related to recreational cannabis.
Key Individual - Nicola Broughton has 20 years experience in VC (six years as investment director), life science and tech sectors with significant expertise in working with academic research groups, spinoffs, and early stage investments. Nicola has significant experience as a non- executive director in life science and software companies.
Key Individual - Alexandre Ouimet-Storrs is a Chemical engineer (B.Eng/M.Eng) with 10 years of venture capital experience in deeptech, industrial and corporate. Involved in more than 19 investments and 60 transactions (over €100m invested) during his time with Truffle Capital and Solvay Ventures.
Key Individual – Oliver Lamb is an experienced European cannabis and controlled environment agriculture consultant. He also has experience as a director and board member for UK cannabis companies. He was involved with creating a machine learning market monitoring algorithm at Morgan Stanley.
High / Adventurous. Capital at Risk.
Invests inServices and solutions surrounding the endocannabinoid system.
3x return after eight years
Not a reliable indicator of future income.
CURRENT STATUS - OPEN
Open to new investors. The fund is an evergreen fund.
The minimum investment is £10,000 (subject to the Investment Manager's discretion to accept smaller amounts).
Alexandre Ouimet-Storrs, Óskare Capital UK Ltd.
What do we look for?
The Fund employs a strict investment process in order to maximise the ability to invest in the best companies whilst minimising the risk of losses.
Octarine harnesses is synthetic biotechnology company with proprietary glycosylation and other functionalisation technologies (platform).
Initial Fee 3%
Annual Management Fee 0.5%
Performance Fee 20%*
*Performance fee is subject to a hurdle rate which must see £1 returned for each £1 invested before the performance bonus is payable.
If an Investor requests that a payment is made to their IFA or Intermediary for advice received, this will be deducted from the
Investor’s Subscription monies, before their investment is made in the Investee Companies.
Please check the fees section of the Information Memorandum for full details. All fees and charges are stated exclusive of VAT, which may be applicable in some cases. Any fees and charges payable by the investee companies or the underlying businesses do not directly come out of your investment. However, they will effectively reduce the returns generated by investee companies and therefore directly impact your investment.
To invest, you must be an eligible investor. To be an eligible investor, you must be qualifying as one or more of the following:
Important information for private investors – Reliance on the information provided here to engage in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Your attention is drawn to the risk section contained within the Information Memorandum. Investments are typically in unquoted shares in small companies, the value of which can be volatile and are often difficult to sell. Nothing on this website constitutes investment, tax, financial, legal, regulatory, or other advice by Sapphire Capital Partners LLP.
The value of an investment may go down as well as up, and you may not get back the full amount invested, and you may therefore lose some or all of your investment.
If you are unsure of the suitability of any investment for your circumstances, please contact your independent financial advisor or other professional advisor authorised under the Financial Services and Markets Act 2000 (FSMA) who specialises in advising on investments of this type. Tax reliefs depend on individual circumstances. There is no guarantee however that the tax reliefs (such as EIS reliefs, CGT reliefs or IHT relief) will be available on any investment made or that if it is initially available, it will not be subsequently withdrawn. Any references to tax laws or rates are based on current legislation, all of which are subject to change and are provided as a guide only. Prospective investors are advised to take their own investment and taxation advice and should consult their own professional advisors on the implications of investing.
Investments made in investee companies via funds managed by Sapphire Capital Partners LLP are not covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk
Past performance is not a guide to future returns.